Execs On The Move: August 2022
Executive Summary
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
You may also be interested in...
Doc On Call? Cosmetic Manufacturers May Need M.D. On Retainer Under MoCRA
Cosmetic manufacturers may need to retain a medical professional to determine if adverse events they receive are minor or serious given the looming deadline for maintaining records and reporting serious adverse events to the US FDA, says Locke Lord partner David Abramowitz.
AstraZeneca/Sanofi’s Nirsevimab Nears US FDA Approval After Overwhelmingly Positive Adcomm
When patients should receive the RSV prevention treatment was the subject of much debate even as the Antimicrobial Drugs Advisory Committee voted nearly unanimously that it should be approved for infants and neonates.